Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Hamlet BioPharma

5,12 SEK

+4,07 %

Mindre end 1K følgere

HAMLET B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+4,07 %
+8,94 %
-14,81 %
+25,95 %
+36,90 %
+59,50 %
+47,00 %
-28,95 %
+131,42 %

Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.

Læs mere
Markedsværdi
945,47 mio. SEK
Aktieomsætning
120,7 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
13.2
2026

Delårsrapport Q2'26

22.5
2026

Delårsrapport Q3'26

28.8
2026

Årsrapport '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse19.11.2025, 07.20

BioStock: Video from Hamlet Biopharma's presentation at BioStock Life Science Summit 202

Hamlet BioPharma
Selskabsmeddelelse14.11.2025, 08.00

Hamlet BioPharma AB (publ): Q1 INTERIM REPORT JULY - SEPT 2025

Hamlet BioPharma
Selskabsmeddelelse10.11.2025, 08.00

Hamlet BioPharma AB (publ): Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non-Muscle Invasive Bladder Cancer

Hamlet BioPharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse5.11.2025, 13.00

Hamlet BioPharma AB (publ): Clinical study in infants with febrile kidney infection supports Hamlet BioPharma's strategy for non-antibiotic treatment of bacterial infections

Hamlet BioPharma
Pressemeddelelse24.10.2025, 14.10

Hamlet BioPharma AB (publ): Clinical studies paving the way for non-antibiotic treatments of bacterial infections; details from the large-scale international study in infants

Hamlet BioPharma
Pressemeddelelse24.10.2025, 14.10

Hamlet BioPharma AB (publ): A new approach to treating bacterial infections without antibiotics - targeting the disease response rather than the bacteria

Hamlet BioPharma
Pressemeddelelse23.9.2025, 07.00

Hamlet BioPharma AB (publ): Monthly investor meeting on the 25th of September

Hamlet BioPharma
Pressemeddelelse22.9.2025, 11.53

Hamlet BioPharma AB (publ): Hamlet BioPharma prepares for next steps and secures drug manufacturing of Alpha1H at Phase III quality

Hamlet BioPharma
Pressemeddelelse9.9.2025, 10.35

Hamlet BioPharma AB (publ): Hamlet BioPharma secures new patents to develop scientific discoveries into drugs for the treatment of cancer and infections

Hamlet BioPharma
Pressemeddelelse4.9.2025, 08.38

Hamlet BioPharma AB (publ): Doctoral thesis to be defended today: Title `'Tumor response mechanisms and treatment effects of alpha1-oleate''

Hamlet BioPharma
Selskabsmeddelelse28.8.2025, 07.00

Hamlet BioPharma AB (publ): Year-end Report (Q4) July 2024 - June 2025

Hamlet BioPharma
Selskabsmeddelelse21.8.2025, 09.15

Hamlet BioPharma AB (publ): Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer

Hamlet BioPharma
Selskabsmeddelelse18.7.2025, 12.58

Hamlet BioPharma AB (publ): Hamlet BioPharma proposes a directed new share issue to finance continued development and commercialization based on three positive Phase II studies

Hamlet BioPharma
Pressemeddelelse25.6.2025, 13.50

Hamlet BioPharma AB (publ): Hamlet BioPharma Holds Successful In Person Meeting with US FDA

Hamlet BioPharma
Pressemeddelelse17.6.2025, 12.06

Hamlet BioPharma AB (publ): Hamlet BioPharma announces progress in Tuberculosis therapy

Hamlet BioPharma
Pressemeddelelse17.6.2025, 08.00

Hamlet BioPharma AB (publ): Hamlet BioPharma invites to investor meeting on the 18th of June

Hamlet BioPharma
Selskabsmeddelelse22.5.2025, 07.00

Hamlet BioPharma AB (publ): Q3 INTERIM REPORT JANUARY - MARCH 2025

Hamlet BioPharma
Pressemeddelelse19.5.2025, 11.21

Hamlet BioPharma AB (publ): Scientific Breakthrough in Alpha1H's Mechanism of Action

Hamlet BioPharma
Pressemeddelelse22.4.2025, 12.38

Hamlet BioPharma AB (publ): Hamlet BioPharma invites to investor meeting on the 23rd of April

Hamlet BioPharma
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.